Isarna Therapeutics GmbH - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "Isarna Therapeutics GmbH - Product Pipeline Review - 2014" provides data on the Isarna Therapeutics GmbH's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Isarna Therapeutics GmbH's corporate website, SEC filings, investor presentations and featured press releases, both from Isarna Therapeutics GmbH and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Isarna Therapeutics GmbH - Brief Isarna Therapeutics GmbH overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Isarna Therapeutics GmbH human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Isarna Therapeutics GmbH with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Isarna Therapeutics GmbH's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Isarna Therapeutics GmbH's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Isarna Therapeutics GmbH in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Isarna Therapeutics GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Isarna Therapeutics GmbH.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Isarna Therapeutics GmbH and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Isarna Therapeutics GmbH Snapshot 5
Isarna Therapeutics GmbH Overview 5
Key Information 5
Key Facts 5
Isarna Therapeutics GmbH - Research and Development Overview 6
Key Therapeutic Areas 6
Isarna Therapeutics GmbH - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Isarna Therapeutics GmbH - Pipeline Products Glance 11
Isarna Therapeutics GmbH - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Isarna Therapeutics GmbH - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Isarna Therapeutics GmbH - Drug Profiles 15
trabedersen 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
AP-11014 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
ASPH-0047 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
ASPH-1047 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Next Generation Oligonucleotides 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Antisense Oligodeoxynucleotides to Inhibit pan TGF-beta for Cancer 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Antisense Oligodeoxynucleotides to Inhibit TGF-beta 1 and 2 for Cancer 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Antisense Oligodeoxynucleotides to Inhibit TGF-beta1 and 3 for Cancer 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Antisense Oligodeoxynucleotides to Inhibit TGF-beta2 and 3 for Cancer 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Antisense Oligodeoxynucleotides to Inhibit TGF-beta3 for Cancer 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
AP-15012 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
NCE For Neoplasms 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Isarna Therapeutics GmbH - Pipeline Analysis 30
Isarna Therapeutics GmbH - Pipeline Products by Therapeutic Class 30
Isarna Therapeutics GmbH - Pipeline Products by Target 31
Isarna Therapeutics GmbH - Pipeline Products by Route of Administration 32
Isarna Therapeutics GmbH - Pipeline Products by Molecule Type 33
Isarna Therapeutics GmbH - Pipeline Products by Mechanism of Action 34
Isarna Therapeutics GmbH - Recent Pipeline Updates 35
Isarna Therapeutics GmbH - Dormant Projects 38
Isarna Therapeutics GmbH - Discontinued Pipeline Products 39
Discontinued Pipeline Product Profiles 39
trabedersen 39
Isarna Therapeutics GmbH - Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables
Isarna Therapeutics GmbH, Key Information 5
Isarna Therapeutics GmbH, Key Facts 5
Isarna Therapeutics GmbH - Pipeline by Indication, 2014 8
Isarna Therapeutics GmbH - Pipeline by Stage of Development, 2014 9
Isarna Therapeutics GmbH - Monotherapy Products in Pipeline, 2014 10
Isarna Therapeutics GmbH - Phase II, 2014 11
Isarna Therapeutics GmbH - Phase I, 2014 12
Isarna Therapeutics GmbH - Preclinical, 2014 13
Isarna Therapeutics GmbH - Discovery, 2014 14
Isarna Therapeutics GmbH - Pipeline by Therapeutic Class, 2014 30
Isarna Therapeutics GmbH - Pipeline by Target, 2014 31
Isarna Therapeutics GmbH - Pipeline by Route of Administration, 2014 32
Isarna Therapeutics GmbH - Pipeline by Molecule Type, 2014 33
Isarna Therapeutics GmbH - Pipeline Products by Mechanism of Action, 2014 34
Isarna Therapeutics GmbH - Recent Pipeline Updates, 2014 35
Isarna Therapeutics GmbH - Dormant Developmental Projects,2014 38
Isarna Therapeutics GmbH - Discontinued Pipeline Products, 2014 39
Isarna Therapeutics GmbH, Other Locations 40